ABCL Q4 2023 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-57.4% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$66M-719.6% margin

Net Income

-$47M-513.7% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+39.1%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$34M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$336M

Stockholders' Equity

$1.2B

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$22M	-57.4%
Gross Profit	$9M	$20M	-54.1%
Operating Income	-$66M	-$38M	-74.8%
Net Income	-$47M	-$30M	-57.7%

Revenue Segments

Research Fees

$9M95%

Milestone Payments

$250,0003%

License

$185,0002%